Navigation Links
Two Pharmaceutical Executives Join TheraQuest Management Team

BLUE BELL, Pa., June 24 /PRNewswire/ -- TheraQuest Biosciences, Inc., a clinical stage pain management company today announced the appointment of Dr. Danny Kao, PhD, JD, as Senior Vice President, Pharmaceutical Development and General Counsel and Douglas R. Baum, MS as Senior Vice President, Business Development. On June 22, 2010, TheraQuest unveiled its analgesic product pipeline and provided a status update on its lead programs in chronic pain and neuropathic pain.

Dr. Najib Babul, CEO, said, "We have added two seasoned executives with more than 30 years of combined analgesic drug development experience to our senior management team.  The addition of outstanding, multi-talented pharma executives like Danny and Doug is a key step in TheraQuest's evolution as a company. Combined with our new product line-up, this move positions TheraQuest for significant progress in near future."

Biographical Summary of Management Team Additions

Danny Kao, PhD, JD joins TheraQuest as Senior Vice President, Pharmaceutical Development and General Counsel. Previously, Dr. Kao was Director, Strategic Development and Director, Formulation Development at Endo Pharmaceuticals.  Dr. Kao has developed several extended release dosage forms, including first to file generic formulations bioequivalent to OxyContin® and MS Contin®.  Dr. Kao received his master's degree in industrial pharmacy from the St. John's University, New York, his PhD in pharmaceutical sciences from the University of Kentucky and his JD from Touro College Law Center. Dr. Kao is a registered patent attorney at the USPTO and is admitted to practice law in New York and New Jersey.

Douglas R. Baum, MS joins TheraQuest as Senior Vice President, Business Development. Mr. Baum has been involved in analgesic drug development for over 20 years with SCIREX Corporation and with its new corporate entity, Premier Research Group.  He has extensive business development experience, working across a number of classes and formulations of analgesics. Mr. Baum served as VP, Strategic Development in the Analgesia & Rheumatology at SCIREX and later as Senior VP, Early Development Unit and VP, Global Business Development at Premier Research. He has significant operational experience with P&L responsibility, having served as Project Director and Program Director in analgesia. Mr. Baum has authored over 20 scientific publications in the field of pain. He received his bachelor's and master's degree from the University of Texas at Austin.

SOURCE TheraQuest Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
2. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
3. K-V Pharmaceutical Company Announces the Nomination and Appointment of New Independent Member to the Board of Directors
4. Pharmaceutical Market Research: A Strategic Business Partner in 2011
5. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
6. Effective Social Media Marketing Strategies for Pharmaceutical Market (2010 - 2015): MarketsandMarkets
7. CSafe Signs Master Lease With Cathay Pacific Airways to Further Enhance Healthcare and Pharmaceutical Transport
8. Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference
9. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
10. Pharmaceutical and Biotech Executives Must Manage and Optimize Key Opinion Leaders or Fall Behind in the Marketplace
11. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... ingredient list of its hemorrhoid ointment to its website. , “Our goal is ... people suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority is ... When you have dental problems, you need to turn to a dentist who listens ... treat your needs, a friendly dentist who counsels you on the best ways to ...
(Date:11/30/2015)... ... ... Dr. Seth D. Margulies specializes in orthodontics and is based in Perth ... the best available orthodontic experience in the area. Dr. Margulies has met all ... the branch of dentistry that specializes in the diagnosis, prevention, and treatment of dental ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
Breaking Medicine News(10 mins):